Cited by 374DNA Repair MechanismsChromatin Remodeling and CancerGenomics and Chromatin Dynamics

The DOI matches its Crossref record; 55 of the 56 references it cites were found in a registry or an index.

Regulation of DNA‐damage responses and cell‐cycle progression by the chromatin remodelling factor CHD4

Open access

Abstract

The chromatin remodelling factor chromodomain helicase DNA‐binding protein 4 (CHD4) is a catalytic subunit of the NuRD transcriptional repressor complex. Here, we reveal novel functions for CHD4 in the DNA‐damage response (DDR) and cell‐cycle control. We show that CHD4 mediates rapid poly(ADP‐ribose)‐dependent recruitment of the NuRD complex to DNA‐damage sites, and we identify CHD4 as a phosphorylation target for the apical DDR kinase ataxia‐telangiectasia mutated. Functionally, we show that CHD4 promotes repair of DNA double‐strand breaks and cell survival after DNA damage. In addition, we show that CHD4 acts as an important regulator of the G1/S cell‐cycle transition by controlling p53 deacetylation. These results provide new insights into how the chromatin remodelling complex NuRD contributes to maintaining genome stability. This paper adds to the emerging concept that chromatin remodelling contributes to DNA‐damage responses. CHD4, a known NuRD component, is identified as ATM target, localizes to DNA breaks and contributes to repair while associating with PARPylated factors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/emboj.2010.188

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 CHD4 is recruited to sites of laser-induced DNA damage within the NuRD complex. (A) Immunodetection of CHD4 and γH2AX (damage sites) at the indicated times after laser micro-irradiation in U2OS cells. (B) Recruitment of NuRD complex subunits to sites of laser-induced DNA damage (labelled by γH2AX) 5 min after micro-irradiation in U2OS cells. (C, D) Immunodetection of HDAC1 and CHD4 5 min after laser micro-irradiation in U2OS cells treated with the indicated siRNAs (siLuci: control). Cells were pre-treated with ATM inhibitor to facilitate detection of HDAC1 and CHD4 lines. Lower panels show siRNA efficiency. In laser micro-irradiation experiments, detergent pre-extraction was performed before fixation of the cells for immunostaining. Scale bars, 10 μm.
Figure 1 CHD4 is recruited to sites of laser-induced DNA damage within the NuRD complex. (A) Immunodetection of CHD4 and γH2AX (damage sites) at the indicated times after laser micro-irradiation in U2OS cells. (B) Recruitment of NuRD complex subunits to sites of laser-induced DNA damage (labelled by γH2AX) 5 min after micro-irradiation in U2OS cells. (C, D) Immunodetection of HDAC1 and CHD4 5 min after laser micro-irradiation in U2OS cells treated with the indicated siRNAs (siLuci: control). Cells were pre-treated with ATM inhibitor to facilitate detection of HDAC1 and CHD4 lines. Lower panels show siRNA efficiency. In laser micro-irradiation experiments, detergent pre-extraction was performed before fixation of the cells for immunostaining. Scale bars, 10 μm.CC BY-NC-SA · PubMed Central
Figure 2 PARP-dependent recruitment of CHD4 to sites of DNA damage. (A) Immunodetection of CHD4 and γH2AX (damage sites) at the indicated times after laser micro-irradiation in U2OS (left) and A-T cells (right). Cells were pre-incubated for 1 h with the indicated inhibitors (ATMi, ATM inhibitor; PARPi, PARP inhibitor) before micro-irradiation. (B) PAR-binding assay with immunoprecipitated GFP-CHD4 wild-type (WT: residues 1–1937) or truncated mutants (N: residues 1–758; C: residues 1183–1937). GFP only is used as a negative control and GFP-APLF as a positive control. Right panel: corresponding Ponceau staining of the blot after immunoprecipitation from HEK-293 cells. (C) Recruitment of GFP-CHD4 wild-type (WT) or a truncated mutant (C: residues 1183–1937) to sites of laser-induced damage (γH2AX) 5 min after micro-irradiation in U2OS cells. In all cases, detergent pre-extraction was performed before fixation of the cells for immunostaining. Scale bars, 10 μm.
Figure 2 PARP-dependent recruitment of CHD4 to sites of DNA damage. (A) Immunodetection of CHD4 and γH2AX (damage sites) at the indicated times after laser micro-irradiation in U2OS (left) and A-T cells (right). Cells were pre-incubated for 1 h with the indicated inhibitors (ATMi, ATM inhibitor; PARPi, PARP inhibitor) before micro-irradiation. (B) PAR-binding assay with immunoprecipitated GFP-CHD4 wild-type (WT: residues 1–1937) or truncated mutants (N: residues 1–758; C: residues 1183–1937). GFP only is used as a negative control and GFP-APLF as a positive control. Right panel: corresponding Ponceau staining of the blot after immunoprecipitation from HEK-293 cells. (C) Recruitment of GFP-CHD4 wild-type (WT) or a truncated mutant (C: residues 1183–1937) to sites of laser-induced damage (γH2AX) 5 min after micro-irradiation in U2OS cells. In all cases, detergent pre-extraction was performed before fixation of the cells for immunostaining. Scale bars, 10 μm.CC BY-NC-SA · PubMed Central
Figure 3 ATM-dependent phosphorylation of CHD4 Ser-1346 in response to DNA damage. (A) Detection of CHD4 phosphorylation (αphos-Ab) 1 h after exposure to 10 Gy ionizing radiation (+ IR) on HA immunoprecipitates from U2OS cells transiently expressing HA-CHD4 wild-type (WT) or S1346A point mutant (SA). The scheme represents CHD4 protein with the amino-acid position of the candidate phospho-serine (S1346); the N and C fragments correspond to CHD4 truncated mutants analysed in Figures 2 and 4. Domain organization of CHD4: NLS (putative nuclear localization signal), PHD (plant homeodomain), CHROMO (chromodomain), DEXH (ATP-binding domain), HELIC (helicase carboxyl-terminal domain). (B) Detection of CHD4 S1346 phosphorylation (αphos-Ab) 30 min after cell exposure to 10 Gy ionizing radiation (IR) on HA immunoprecipitates from U2OS cells transiently expressing HA-CHD4. Cells were pre-treated with the indicated inhibitors (W, Wortmannin; PKi, DNA-PK inhibitor; ATMi, ATM inhibitor). ATM-dependent phosphorylation of SMC1 S966 and DNA-PKcs autophosphorylation on S2056 are used as controls.
Figure 3 ATM-dependent phosphorylation of CHD4 Ser-1346 in response to DNA damage. (A) Detection of CHD4 phosphorylation (αphos-Ab) 1 h after exposure to 10 Gy ionizing radiation (+ IR) on HA immunoprecipitates from U2OS cells transiently expressing HA-CHD4 wild-type (WT) or S1346A point mutant (SA). The scheme represents CHD4 protein with the amino-acid position of the candidate phospho-serine (S1346); the N and C fragments correspond to CHD4 truncated mutants analysed in Figures 2 and 4. Domain organization of CHD4: NLS (putative nuclear localization signal), PHD (plant homeodomain), CHROMO (chromodomain), DEXH (ATP-binding domain), HELIC (helicase carboxyl-terminal domain). (B) Detection of CHD4 S1346 phosphorylation (αphos-Ab) 30 min after cell exposure to 10 Gy ionizing radiation (IR) on HA immunoprecipitates from U2OS cells transiently expressing HA-CHD4. Cells were pre-treated with the indicated inhibitors (W, Wortmannin; PKi, DNA-PK inhibitor; ATMi, ATM inhibitor). ATM-dependent phosphorylation of SMC1 S966 and DNA-PKcs autophosphorylation on S2056 are used as controls.CC BY-NC-SA · PubMed Central
Figure 4 DNA-damage-induced phosphorylation and recruitment of CHD4 to DNA lesions are distinct events. (A) Recruitment of HA-CHD4 wild-type (WT) and Ser-1346 point mutants (SA, mutated to Ala; SE, mutated to Glu) to sites of laser-induced damage (γH2AX) in transiently transfected U2OS cells 5 min after micro-irradiation. Scale bar, 10 μm. (B) PAR-binding activity of GFP-CHD4 from HEK-293 cells exposed or not to ionizing radiation (IR). GFP only is used as a negative control, GFP-APLF as a positive control. Lower panel shows CHD4 phosphorylation after IR analysed in parallel by western blotting. (C) Detection of CHD4 phosphorylation (αphos-Ab) 30 min after exposure to 10 Gy ionizing radiation (IR) or 500 μM hydrogen peroxide (H2O2) on CHD4 immunoprecipitates from HEK-293 cells treated or not with PARP inhibitor (PARPi). SMC1 phosphorylation is used as a control for DNA damage. The NuRD subunit HDAC1 co-immunoprecipitates with CHD4. (D) Detection of CHD4 phosphorylation (αphos-Ab) 30 min after exposure to 10 Gy ionizing radiation (IR) on GFP immunoprecipitates from H3K293 cells transiently expressing GFP-CHD4 wild-type (WT) or a truncated mutant (C: residues 1183–1937).
Figure 4 DNA-damage-induced phosphorylation and recruitment of CHD4 to DNA lesions are distinct events. (A) Recruitment of HA-CHD4 wild-type (WT) and Ser-1346 point mutants (SA, mutated to Ala; SE, mutated to Glu) to sites of laser-induced damage (γH2AX) in transiently transfected U2OS cells 5 min after micro-irradiation. Scale bar, 10 μm. (B) PAR-binding activity of GFP-CHD4 from HEK-293 cells exposed or not to ionizing radiation (IR). GFP only is used as a negative control, GFP-APLF as a positive control. Lower panel shows CHD4 phosphorylation after IR analysed in parallel by western blotting. (C) Detection of CHD4 phosphorylation (αphos-Ab) 30 min after exposure to 10 Gy ionizing radiation (IR) or 500 μM hydrogen peroxide (H2O2) on CHD4 immunoprecipitates from HEK-293 cells treated or not with PARP inhibitor (PARPi). SMC1 phosphorylation is used as a control for DNA damage. The NuRD subunit HDAC1 co-immunoprecipitates with CHD4. (D) Detection of CHD4 phosphorylation (αphos-Ab) 30 min after exposure to 10 Gy ionizing radiation (IR) on GFP immunoprecipitates from H3K293 cells transiently expressing GFP-CHD4 wild-type (WT) or a truncated mutant (C: residues 1183–1937).CC BY-NC-SA · PubMed Central
Figure 5 CHD4 regulates cell sensitivity to DNA damage. (A) γH2AX foci formation in U2OS cells upon CHD4 depletion (siCHD4) compared with control (siLuci) 1 h after exposure to 10 Gy ionizing radiation (IR). (B) Phosphorylation of DNA-damage checkpoint proteins analysed by western blotting of total extracts prepared from HeLa cells at the indicated times after cell exposure to 10 Gy ionizing radiation (IR) (siCHD4, CHD4 depletion; siLuci, control). (C) Recruitment of MDC1, 53BP1 and BRCA1 to sites of laser-induced damage (γH2AX) 5–10 min after micro-irradiation in HeLa cells upon CHD4 depletion (siCHD4) compared with control (siLuci). Detergent pre-extraction was performed before fixation and immunostaining for BRCA1. Scale bars, 10 μm. (D) Efficiency of DSB repair in control (siLuci) or CHD4-depleted U2OS cells analysed by neutral comet assay after phleomycin treatment (Phleo). Error bars: s.d. from two independent experiments. (E) Clonogenic survival of U2OS cells upon CHD4 knock-down (siCHD4) compared with control (siLuci) in response to ionizing radiation (IR) or hydrogen peroxide (H2O2). H2O2 treatment was for 10 min at the indicated doses. Error bars indicate s.d. from two and three independent experiments, respectively. The results are normalized to plating efficiencies to focus on the effect of CHD4 depletion upon DNA damage. Note that in the absence of DNA-damaging agent, the viability of CHD4-depleted cells is ∼66% of that of control cells.
Figure 5 CHD4 regulates cell sensitivity to DNA damage. (A) γH2AX foci formation in U2OS cells upon CHD4 depletion (siCHD4) compared with control (siLuci) 1 h after exposure to 10 Gy ionizing radiation (IR). (B) Phosphorylation of DNA-damage checkpoint proteins analysed by western blotting of total extracts prepared from HeLa cells at the indicated times after cell exposure to 10 Gy ionizing radiation (IR) (siCHD4, CHD4 depletion; siLuci, control). (C) Recruitment of MDC1, 53BP1 and BRCA1 to sites of laser-induced damage (γH2AX) 5–10 min after micro-irradiation in HeLa cells upon CHD4 depletion (siCHD4) compared with control (siLuci). Detergent pre-extraction was performed before fixation and immunostaining for BRCA1. Scale bars, 10 μm. (D) Efficiency of DSB repair in control (siLuci) or CHD4-depleted U2OS cells analysed by neutral comet assay after phleomycin treatment (Phleo). Error bars: s.d. from two independent experiments. (E) Clonogenic survival of U2OS cells upon CHD4 knock-down (siCHD4) compared with control (siLuci) in response to ionizing radiation (IR) or hydrogen peroxide (H2O2). H2O2 treatment was for 10 min at the indicated doses. Error bars indicate s.d. from two and three independent experiments, respectively. The results are normalized to plating efficiencies to focus on the effect of CHD4 depletion upon DNA damage. Note that in the absence of DNA-damaging agent, the viability of CHD4-depleted cells is ∼66% of that of control cells.CC BY-NC-SA · PubMed Central
Figure 6 CHD4 controls the G1/S cell-cycle transition through p53 deacetylation. (A) Fluorescence-activated cell sorting (FACS) profiles of U2OS cells downregulated for CHD4 (siCHD4) compared with control (siLuci). Percentages of cells in G1 are indicated. Nocodazole was used to block cell-cycle progression in mitosis (bottom panels). (B) Western-blot analysis of total extracts from U2OS cells downregulated for CHD4 (siCHD4) compared with control (siLuci) using the indicated antibodies. (C) Quantitative RT–PCR analysis of p21, p53 and β-actin mRNA levels in U2OS cells downregulated for CHD4 (siCHD4) compared with control (siLuci). Error bars indicate s.d. from two independent experiments. (D) Western-blot analysis of p21 induction on total extracts from p53 proficient or deficient HCT116 cells upon CHD4 depletion (C) compared with control siLuciferase (L). + IR: 9 h post-exposure to 10 Gy IR. (E, F) Western-blot analysis of total extracts from U2OS cells treated with the indicated siRNAs. Phleo: 1 h post-exposure to 60 μg/ml Phleomycin. (G) FACS profiles of U2OS cells treated with the indicated siRNAs. Nocodazole was used to block cell-cycle progression in mitosis.
Figure 6 CHD4 controls the G1/S cell-cycle transition through p53 deacetylation. (A) Fluorescence-activated cell sorting (FACS) profiles of U2OS cells downregulated for CHD4 (siCHD4) compared with control (siLuci). Percentages of cells in G1 are indicated. Nocodazole was used to block cell-cycle progression in mitosis (bottom panels). (B) Western-blot analysis of total extracts from U2OS cells downregulated for CHD4 (siCHD4) compared with control (siLuci) using the indicated antibodies. (C) Quantitative RT–PCR analysis of p21, p53 and β-actin mRNA levels in U2OS cells downregulated for CHD4 (siCHD4) compared with control (siLuci). Error bars indicate s.d. from two independent experiments. (D) Western-blot analysis of p21 induction on total extracts from p53 proficient or deficient HCT116 cells upon CHD4 depletion (C) compared with control siLuciferase (L). + IR: 9 h post-exposure to 10 Gy IR. (E, F) Western-blot analysis of total extracts from U2OS cells treated with the indicated siRNAs. Phleo: 1 h post-exposure to 60 μg/ml Phleomycin. (G) FACS profiles of U2OS cells treated with the indicated siRNAs. Nocodazole was used to block cell-cycle progression in mitosis.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Cited by

Sorted by citations

Items 201–300 of 374

Metadata

Authors
Polo, S. E., Kaidi, A., Baskcomb, L., Galanty, Y., & Jackson, S. P.
Affiliations
University of Cambridge (GB)
Corresponding author
Jackson, Stephen P
Venue
The EMBO Journal
Published
2010-08-06
Volume
29
Issue
18
Pages
3130-3139
ISSN
  • 0261-4189 (ISSN-L)
  • 1460-2075
OpenAlex
W2020084014
Cited by
374
References
56
Citations by year
2026: 13 · 2025: 14 · 2024: 20 · 2023: 17 · 2022: 26 · 2021: 17 · 2020: 22 · 2019: 18 · 2018: 18 · 2017: 35 · 2016: 24 · 2015: 17 · 2014: 31 · 2013: 34 · 2012: 31
FWCI
13.30
Type
journal article
Language
en
Open access
Locations
  • The EMBO Journal (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Explore Bristol Research (submittedVersion)
Funders
  • Wellcome Trust
  • Cancer Research UK (11224, A5290, A4361)
  • European Commission (512113, 201630, LSHG-CT-2005-512113)
  • Directorate for Biological Sciences
  • Biotechnology and Biological Sciences Research Council
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
Keywords
CHD4, chromatin remodeling, NuRD complex, DNA damage response, cell cycle regulation, G1/S transition, p53 deacetylation, ATM phosphorylation, DNA double-strand break repair, poly(ADP-ribose), poly(ADP-ribose) polymerase, genome stability, transcriptional repressor
MeSH terms
Animals, Autoantigens, Cell Cycle, DNA Damage, DNA Helicases, DNA-Binding Proteins, Fluorescent Antibody Technique, Histones, Humans, Phosphorylation, Poly Adenosine Diphosphate Ribose, RNA, Messenger, Blotting, Western, Tumor Suppressor Protein p53, Protein Serine-Threonine Kinases, Mice, Knockout, Cell Cycle Proteins, Reverse Transcriptase Polymerase Chain Reaction, Tumor Suppressor Proteins, Chromatin Assembly and Disassembly, Immunoprecipitation, Mice, Mi-2 Nucleosome Remodeling and Deacetylase Complex, Ataxia Telangiectasia Mutated Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review